Safety Study of Kudiezi(Yueanxin,a Chinese Medicine Injection)Used in Hospitals in China
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study was advocated by institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences in October 2011.
It was funded by China major scientific and technological specialized specialized project for 'significant new formulation of net drugs'.
Kudiezi(Yueanxin) is kind of Chinese Medicine injiection used for treating corinary heart diswese、angina pectoris and stroke in many Chinese hospitals.
The purpose of this study is to determine adverse drug events or adverse drug reaction in large sample size 30,000 patients.
| Condition |
|---|
|
Coronary Heart Disease Angina Pectoris Stroke |
| Study Type: | Observational [Patient Registry] |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Target Follow-Up Duration: | 14 Days |
| Official Title: | Registry Study Intensive Hospital Monitoring Protocol of Kudiezi Injection ( Yueanxin ) 's Clinical Safety |
- Number of participants with adverse events;incidence of Kudiezi(Yueanxin)'ADRs and identify factors that contributed to the occurrence of the adverse reaction [ Time Frame: to assess Kudiezi(Yueanxin)'s 'adverse event' and 'drug adverse reaction' during patients' hospital stay,administration information of Kudiezi will be registered every day.The registry procedure will last 3 years only for patients using Kudiezi. ] [ Designated as safety issue: Yes ]All patients will be measured and assessed at the time Kudiezi(Yueanxin) is adminnistered to them until they discharge.Patients using Kudiezi(Yueanxin) will be registered on a regisration form including disease background, Kudiezi(Yueanxin)'s adminidtration,and extraction information from hospital information system.An adverse event or drug adverse reaction form also will be used to describe any doubted symptoms or signs from patients.A judgment will be made by doctors directly and a further analysis will be conducted by researchers to decide those potential side effects of Kudiezi(Yueanxin).
| Estimated Enrollment: | 30000 |
| Study Start Date: | January 2012 |
| Estimated Study Completion Date: | December 2015 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
It is very common that Chinese Medicine Injection used in hospitals in mainland China.However safety problems rose in recent years.There could be many uncertain factors influence Chinese Medincine Injection in clinical practice.
Safety surveillance on Chinese Medincine injection is an important problem that needs to be sorted out through large sample observational dtudy.
A registry study for Kudiezi(Yueanxin) injection safety surveillance with 30000 patients will be conducted form Jan.2012 to Dec.2015.
Eligiblity crteria Patients who will use Kudiezi(Yueanxin) injection in selected hospitals.
Date will be collected in four aspects by four different forms as following:
Form A(blue):demographic information ;Form B(yellow):adverde drug events/reaction;Form C(white):extracted information from hodpiral information system and laboratory information system.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
An anticpcipated sample size was caculated in this study,about 30000.Patients using Kudiezi injection from 2012 to 2014 in more than 20 hospital.
Inclusion Criteria:
Patients using Kudiezi(Yueanxin) injection from 2012 to 2014
Exclusion Criteria:
none
Contacts and Locations| China, Beijing | |
| Institute of Basic Research in Clinical Medicine | |
| Beijing, Beijing, China, 100700 | |
| Principal Investigator: | Xie Y Ming, BA | China Academy of Chinese Medical Sciences |
More Information
No publications provided
| Responsible Party: | Yanming Xie, Deputy Director, China Academy of Chinese Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT01781676 History of Changes |
| Other Study ID Numbers: | RSCMI-Ⅷ |
| Study First Received: | January 30, 2013 |
| Last Updated: | May 13, 2013 |
| Health Authority: | China: State Administration of Traditional Chinese Medicine of the People's Republic of China |
Additional relevant MeSH terms:
|
Angina Pectoris Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases Stroke Cardiovascular Diseases Vascular Diseases Chest Pain |
Pain Signs and Symptoms Arteriosclerosis Arterial Occlusive Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013